Actualización corporativa y suspensión de cotizaciones en AIM
Este anuncio contiene información privilegiada a los efectos del artículo 7 del Reglamento (UE) n.º 596/2014, que forma parte de la legislación del Reino Unido en virtud de la Ley (Retirada) de la Unión Europea de 2018.
5 de febrero de 2024
Grupo ReNeuron plc
("ReNeurona", la "Grupo procesos" o el "Empresa")
Actualización corporativa y suspensión de cotizaciones en AIM
ReNeuron Group plc (AIM: RENE), a UK based leader in stem cell derived exosome technologies, provides the following update in relation to its current business development, financing discussions and working capital position.
On 8 November 2023, the Group announced its Interim Results for the six months ended 30 September 2023 ("Interim Results"). At the time, the Board stated that the outlook for the business remained positive provided it could retain its' highly dedicated team of scientists, further develop and verify the CustomEX? exosome delivery platform and conclude validating industry partnerships.
As also announced in the Interim Results, potential corporate actions that were under consideration by the Board included raising additional equity financing and/or securing a financing facility and/or entering into M&A discussions. The Group also noted in the Interim Results that as at 30 September 2023, the Group had cash, cash equivalents and bank deposits of £5.1 million and that the Group's latest internal projections (assuming no new revenues or funding) meant there was a cash runway to April 2024, ahead of which point further revenues and/or a capital injection would be required.
In the intervening period, despite great scientific progress having been made in further developing and exemplifying the CustomEX? exosome delivery platform and progressing several ongoing third-party business development discussions, the Group has not yet been able to conclude a validating, revenue generating industry partnership nor been able to secure additional equity funding. Accordingly, throughout the period the Group has been carefully managing its working capital, but it is now in a highly constrained financial position and requires additional financing urgently, in order to continue as a going concern. In the absence of any additional financing being available in the immediate term, the Group now needs to take steps to preserve and maximise value for its creditors.
Whilst the Group continues to explore a number of corporate options, including seeking to realise value for its physical and intellectual assets, the Board recognises that in the absence of an immediate injection of capital and in view of the current financial uncertainty, it needs to put staff at risk of redundancy, initiate discussions with its creditors and establish the precise solvency status of the business. Should the Company fail to achieve a solution in the short term, the Board would have no option but to place the Company into administration. Should administrators be appointed, it is not known how much, if any, value would be returned to shareholders.
In light of the above, the Company has requested a suspension of trading in its ordinary shares on AIM pending clarification of its financial position. Trading in the Company's ordinary shares has been suspended at 2:30 p.m. today and further updates will be provided in due course.
Consultas:
ReNeurona | www.reneuron.com/inversores | ||
Iain Ross, presidente ejecutivo | A través de Walbrook PR | ||
John Hawkins, director financiero | |||
Allenby Capital Limited (Asesor designado y Broker) | 44 0 20 3328 5656 | ||
James Reeve/George Payne/Dan Dearden-Williams (Finanzas corporativas) | |||
Stefano Aquilino/Kelly Gardiner (Ventas y corretaje corporativo) | |||
Walbrook PR (Relaciones con inversores y medios) | +44 (0) 20 7933 8780 o GME@dhr-rgv.com | ||
Paul McManus/Alice Woodings | +44 (0) 7980 541 / +893 (44) 0 7407 | ||
Acerca de ReNeuron
ReNeuron ha desarrollado una plataforma patentada de administración de fármacos basada en exosomas y derivada de células madre con capacidades de orientación celular personalizables para la administración de modalidades complejas de fármacos.
A través de la generación de varias líneas celulares productoras de exosomas únicas y escalables, nuestro CustomEX? La plataforma se puede optimizar para objetivos de tejidos y cargas útiles específicos, lo que conduce a mejoras en el resultado terapéutico y una reducción de los efectos fuera del objetivo. ReNeuron ofrece un mecanismo de entrega para una variedad de cargas útiles como ARNip, ARNm, proteínas, moléculas pequeñas y genes. A través de su plataforma de células madre pluripotentes inducidas (iPSC) condicionalmente inmortalizadas, la compañía puede elegir células de tejido alogénicas y tiene el potencial de producir exosomas con capacidad de focalización específica de tejido.
Las acciones de ReNeuron cotizan en el mercado AIM de Londres con el símbolo RENE.L. Para más información visita www.reneuron.com
Este anuncio contiene declaraciones prospectivas con respecto a la situación financiera, los resultados de las operaciones y los logros/desempeño comercial de ReNeuron y algunos de los planes y objetivos de gestión de ReNeuron con respecto a los mismos. Estas declaraciones pueden identificarse generalmente, aunque no siempre, mediante el uso de palabras como "debería", "espera", "estima", "cree" o expresiones similares.
RNS puede usar su dirección IP para confirmar el cumplimiento de los términos y condiciones, para analizar cómo interactúa con la información contenida en esta comunicación y para compartir dicho análisis de forma anónima con otros como parte de nuestros servicios comerciales. Para obtener más información sobre cómo RNS y la Bolsa de Valores de Londres utilizan los datos personales que nos proporciona, consulte nuestra Política de privacidad.